Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 2,507 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Normal protein Clear all

Conditions: Prostate Cancer Metastatic
Interventions: ARV-766, Abiraterone, Corticosteroid (e.g., prednisone/prednisolone), Androgen Deprivation Therapy (ADT); Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 17
States / cities: Duarte, California • La Jolla, California • Santa Monica, California + 14 more

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia
Interventions: Clofarabine, Busulfan, Fludarabine, Stem Cell Infusion, Thymoglobulin (ATG), Filgrastim; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 60 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: recombinant interferon alfa, carmustine, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, melphalan, prednisone, vincristine sulfate, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 70 Years
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2006
U.S. locations: 34
States / cities: Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 25 more

Conditions: Obesity
Interventions: Immediate weight loss, Pioglitazone, Deferred weight loss, Placebo; Behavioral · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Retinitis Pigmentosa
Interventions: Low Dose NT-501, High Dose NT-501; Combination Product
Lead sponsor: Neurotech Pharmaceuticals; Industry
Eligibility: 18 Years to 68 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 11
States / cities: Beverly Hills, California • Sacramento, California • San Francisco, California + 8 more

Conditions: Neuroblastoma, Central Nervous System Tumors, Lymphomas, Wilms Tumor
Interventions: Stem Cell Transplantation, Busulfan, Melphalan; Procedure · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 25 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Prostate Cancer
Interventions: Degarelix, Leuprolide; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: Male only
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 48
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more

Conditions: GBM
Interventions: NaviFUS System, Lumason, Bevacizumab; Device · Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Primary Myelofibrosis, Secondary Myelofibrosis
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Methotrexate, Mycophenolate Mofetil, Ruxolitinib, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation; Procedure · Drug · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Fibrosis (Morphologic Abnormality)
Interventions: [F-18]-FAPI-74; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 21 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pain
Interventions: Botulinum Toxin Type A, Saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Contraception, Hypogonadism
Interventions: Oral Testosterone, Leuprolide (Lupron), Dutasteride; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ovarian Cancer
Interventions: Decitabine, Carboplatin, Paclitaxel, Selinexor; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
Interventions: Busulfan, Fludarabine, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Post-Transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Patient Reported Outcomes, Melphalan, Total-body irradiation, Cyclophosphamide; Drug · Procedure · Other + 1 more
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 18 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 32
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 28 more

Conditions: Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: melphalan, amifostine trihydrate, peripheral blood stem cell transplantation, fluorescence in situ hybridization, bone marrow ablation with stem cell support; Drug · Procedure · Genetic
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 4
States / cities: Los Angeles, California • Rochester, New York • Seattle, Washington

Conditions: Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection, Transplantation, Bone Marrow
Interventions: Melphalan, Fludarabine, Mycophenolate mofetil, Tacrolimus, Cord Blood Infusion, Rituximab, ATG, Busulfan, Clofarabine, Total Body Irradiation (TBI); Drug · Procedure · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 1 Year to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: bicalutamide, docetaxel, goserelin, intensity-modulated radiation therapy; Drug · Radiation
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Adrenal Cortex Diseases, Infant Morbidity
Interventions: Cosyntropin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: Up to 365 Days
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sarcoma
Interventions: DNA analysis, gene expression analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis; Genetic · Other
Lead sponsor: University of Arizona; Other
Eligibility: Not listed
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Prostate Cancer
Interventions: Leuprolide Acetate, Prednisone, Docetaxel, Apalutamide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Topical Antisepsis
Interventions: CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once)., CHG 2% w/v & IPA 70% v/v swab applied sequentially, Aqueous CHG 4% w/v applied according to mfr's directions, Sterile swabstick with sterile water (3 @ once), Sterile swabstick with sterile water (one-at-a-time); Drug · Other
Lead sponsor: C. R. Bard; Industry
Eligibility: 16 Years and older
Enrollment: 335 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Sterling, Virginia

Conditions: Prostate Cancer
Interventions: leuprolide acetate; Drug
Lead sponsor: GP-Pharm; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 15
States / cities: Homewood, Alabama • Casa Granda, Arizona • Fort Myers, Florida + 11 more

Conditions: Kidney Transplant Failure and Rejection
Interventions: Tacrolimus (TAC), Sirolimus, Alemtuzumab, Mycophenolate mofetil (MMF); Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Thyroid Goiter, Hypothyroidism, Thyroid Cancer
Interventions: Levothyroxine, Liothyronine, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Search by objective public record fields.

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

Insulin Regulation of Lipolysis and Lipolysis Proteins

A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa

Chemotherapy With CD133+ Select Autologous Hematopoietic Stem Cells for Children With Solid Tumors and Lymphomas

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma

JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

FAPI-74 PET/CT in Adults With Fibrosis

Subcutaneous Botulinum Toxin for Cutaneous Allodynia - Enriched Responder Trial

Oral Androgens in Man-3 (ORAL T-3) Pharmacokinetics of Oral Testosterone

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer

Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery

Studying Tumor Tissue Samples From Patients With Soft Tissue Sarcoma

A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer

Test for Pre Operative Skin Preparations

Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer

A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression

Energy Metabolism in Thyroidectomized Patients